Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

New algorithm predicts acute liver failure in drug-induced liver injury

This month's issue of Gastroenterology examines the use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury.

News image

Hy's Law, which states that hepatocellular drug-induced liver injury with jaundice indicates a serious reaction, is used widely to determine risk for acute liver failure.

Dr Isabel Lucena and colleagues from Spain optimized the definition of Hy's Law, and developed a model for predicting acute liver failure in patients with drug-induced liver injury.

The researchers collected data from 771 patients with drug-induced liver injury from the Spanish DILI registry, from 1994 through 2012.

The team analyzed data collected at drug-induced liver injury recognition, and at the time of peak levels of alanine aminotransferase (ALT) and total bilirubin.

Of the 771 patients with drug-induced liver injury, 32 developed acute liver failure.

Hepatocellular injury, female sex, high levels of total bilirubin, and a high ratio of aspartate aminotransferase (AST):ALT were independent risk factors for acute liver failure.

An R-based model identified patients who developed acute liver failure with 67% specificity
Gastroenterology

The research team compared 3 ways to use Hy's Law to predict which patients would develop acute liver failure.

All included total bilirubin greater than 2-fold the upper limit of normal (×ULN), and either ALT level greater than 3 × ULN, a ratio (R) value of 5 or greater, or a new ratio (nR) value of 5 or greater.

At recognition of drug-induced liver injury, the R- and nR-based models identified patients who developed acute liver failure with 67% and 63% specificity, respectively, whereas use of only ALT level identified them with 44% specificity.

However, the level of ALT and the nR model each identified patients who developed acute liver failure with 90% sensitivity, whereas the R criteria identified them with 83% sensitivity.

The team found an equal number of patients who did and did not develop ALF had alkaline phosphatase levels greater than 2 × ULN.

The researchers observed that an algorithm based on AST level greater than 17.3 × ULN, total bilirubin greater than 6.6 × ULN, and AST:ALT greater than 1.5 identified patients who developed acute liver failure with 82% specificity and 80% sensitivity.

Dr Lucena's team concludes, "When applied at drug-induced liver injury recognition, the nR criteria for Hy's Law provides the best balance of sensitivity and specificity whereas our new composite algorithm provides additional specificity in predicting the ultimate development of acute liver failure."

Gastroenterol 2014: 147(1): 109–118.e5
03 July 2014

Go to top of page Email this page Email this page to a colleague

 02 April 2015

Advanced search
 02 April 2015 
Physical activity and NAFLD
 02 April 2015 
Genetic risk for Crohn's disease
 02 April 2015 
EUS for detection of pancreatic neuroendocrine tumors
 01 April 2015 
Analysis of liver fibrosis
 01 April 2015 
Obeticholic acid in primary biliary cirrhosis
 01 April 2015 
Mortality rates for upper GI bleeds
 31 March 2015 
HCV-HIV co-infection combination therapy
 31 March 2015 
Placement of nasoenteral feeding tubes
 31 March 2015 
Hepatic fat and gallbladder polyps
 30 March 2015 
Minimally invasive approach in colorectal procedures
 30 March 2015 
Prevalence of IBD in USA residents of Indian ancestry
 30 March 2015 
Treatment of pediatric IBD
 27 March 2015 
Screening for fecal incontinence
 27 March 2015 
Deep remission in Crohn's disease
 27 March 2015 
Sexual functioning in IBD
 26 March 2015 
Survival of untreated hepatocellular carcinoma
 26 March 2015 
Antimicrobial therapy in cirrhosis with spontaneous bacterial peritonitis
 26 March 2015 
Metformin as a chemopreventive agent for Barrett's
 25 March 2015 
Genetics and Crohn's disease
 25 March 2015 
Mortality in Barrett’s–related T1 esophageal adenocarcinoma
 25 March 2015 
Cytomegalovirus and IBD
 24 March 2015 
Prevention of colorectal cancer after screening
 24 March 2015 
Functional GI disorders and body mass index
 24 March 2015 
Quality of life in children with fecal incontinence
 23 March 2015 
Fibrosis in NAFLD vs NASH
 23 March 2015 
The unmasking of Whipple's disease
 23 March 2015 
Predicting the quality of colon cancer care
 20 March 2015 
Interventions for eosinophilic esophagitis
 20 March 2015 
Screening for Barrett's esophagus
 20 March 2015 
Colorectal cancer risk and genetic variants
 19 March 2015 
Dedicated care for diverticular disease
 19 March 2015 
Hypnotherapy for IBS
 19 March 2015 
Poor mental and physical health in HCV
 18 March 2015 
Practice guidelines for colorectal polyps
 18 March 2015 
Out-of-hours endoscopy for upper GI bleeding
 18 March 2015 
H. pylori eradication and lipids
 17 March 2015 
H. pylori test-and-treat program and gastric cancer
 17 March 2015 
Adalimumab in Crohn’s disease
 17 March 2015 

Low-dose PPIs and GI bleeding in patients receiving aspirin

 16 March 2015 
Microscopic colitis
 16 March 2015 
Cholestasis of pregnancy with HCV
 16 March 2015 
Hybrid therapy for H. pylori
 13 March 2015 

Racial disparities in gluten-sensitive problems

 13 March 2015 
Medicare patients and payments to gastroenterologists
 13 March 2015 
Appendectomy in ulcerative colitis
 12 March 2015 
Predicting IBD in IBS patients
 12 March 2015 
Patient knowledge of IBS
 12 March 2015 
Nonceliac gluten sensitivity
 11 March 2015 

Prediction of malignant bile duct obstruction

 11 March 2015 
NAFLD–related hepatocellular carcinoma
 11 March 2015 
Assessment of eosinophilic esophagitis
 10 March 2015 
Risk for gastroesophageal reflux symptoms
 10 March 2015 
Poor disease course in pediatric ulcerative colitis
 10 March 2015 
Outcomes in Crohn's therapy
 09 March 2015 
Fibre usage in ulcerative colitis in remission
 09 March 2015 
Risk of C. difficile upon hospital admission
 09 March 2015 
Gastric Cancer detection during GI endosocopy
 06 March 2015 
Steroid therapy for eosinophilic esophagitis
 06 March 2015 
Second anti-TNF in IBD
 06 March 2015 
Efficacy of Hep E vaccine

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us